Receive Breaking News updates as they occur
China outlined a defense strategy on Tuesday to boost its naval capability farther from its shores, saying it faced a grave and complex array of security threats including in the disputed South China Sea. The document comes as tensions rise over China's increasingly assertive posture in the disputed waters of the South China Sea, where Beijing has engaged in land reclamation in the Spratly archipelago. China, which claims most of the South China Sea, criticized Washington after a U.S. spy plane flew over areas near the reefs last week, with both sides accusing each other of stoking instability in the region.
By Jim Forsyth SAN ANTONIO (Reuters) - Texas Governor Greg Abbott on Monday likened the ferocity of flash flooding that killed at least three people to a tsunami, and authorities said a dam had given way in a state park. Abbott declared states of disaster in 24 counties and flew over the area south of Austin to assess the damage caused by tornadoes, heavy rainfall, thunderstorms and flooding that forced evacuations and rooftop rescues and left thousands of residents without electricity. "This is the biggest flood this area of Texas has ever seen," Abbott said.
By Deena Beasley LOS ANGELES (Reuters) - Two powerful and innovative cholesterol drugs likely to be approved this summer both target the same protein and have been shown to sharply lower LDL in high-risk patients. But there is at least one significant difference between the two offerings: the dosages in which they will be sold. Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. The difference in dosages is likely to lead to very different sales strategies for the two drugs, in what could be a fierce competition for market share.